According to the Zhitong Finance App, Maibo Pharmaceutical-B (02181.HK) announced interim results for the six months ended June 30, 2026. The Group's revenue was RMB 398 million, up 45.1% year on year; profit attributable to shareholders was RMB 31.36 million, up 982.1% year on year; profit per share.

Zhitongcaijing · 1d ago
According to the Zhitong Finance App, Maibo Pharmaceutical-B (02181.HK) announced interim results for the six months ended June 30, 2026. The Group's revenue was RMB 398 million, up 45.1% year on year; profit attributable to shareholders was RMB 31.36 million, up 982.1% year on year; profit per share.